Robert O. Blaustein

机构：Healthwise, Edgewise Therapeutics (United States) · ORCID：0000-0001-8609-3508

发表论文 80 篇 · 总被引 2599 次 · h-index 26

代表论文

• Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science (2023 · Clinical and Translational Science · 被引 48)
• Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials (2025 · The Lancet · 被引 39)
• Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial (2024 · European Journal of Heart Failure · 被引 36)
• Age, Sex, and Outcomes in Heart Failure With Reduced EF (2023 · JACC Heart Failure · 被引 28)
• Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy (2023 · Journal of Cardiac Failure · 被引 15)
• Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction (2023 · JACC Heart Failure · 被引 14)